Literature DB >> 22892674

Is it too early to predict the failure of natalizumab in NMO?

Raghav Govindarajan, Efrain Salgado.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22892674     DOI： 10.1001/archneurol.2012.1138

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  3 in total

1.  [Therapeutic options for autoimmune encephalomyelitis].

Authors:  N Borisow; H Prüss; F Paul
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

2.  Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS.

Authors:  Anna Gahlen; Anne-Kathrin Trampe; Steffen Haupeltshofer; Marius Ringelstein; Orhan Aktas; Achim Berthele; Brigitte Wildemann; Ralf Gold; Sven Jarius; Ingo Kleiter
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-06-16

3.  Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report.

Authors:  De-Hyung Lee; Alexandra B Laemmer; Anne Waschbisch; Tobias Struffert; Christian Maihöfner; Stefan Schwab; Ralf Andreas Linker
Journal:  J Med Case Rep       Date:  2014-05-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.